Multiple Sclerosis (MS) is an inflammatory neurodegenerative disease with distinctive features of focal demyelination, axonal loss, activation of glial cells, and immune cells infiltration. The symptoms of this disease are the consequence of the formation of new lesions in the central nervous system (CNS) and the expansion and aggravation of existing lesions causes its progression. MS can occur in four clinical forms with the relapsing-remitting form (RRMS) being the most prevalent among MS patients. RRMS is identified by the relapsing periods which are acute attacks followed by the remission periods where partial or full recovery takes place. The efficiency of current therapeutic approaches for MS is usually limited by the side effects. Chlorogenic acid (CA) is a natural compound found in a wide range of plant materials and is used in the prevention of many diseases. This review presents preclinical evidence that supports the use of CA in MS treatment protocols.